Matrix metalloproteinase 9/neutrophil gelatinase associated lipocalin/tissue inhibitor of metalloproteinases type 1 complexes are localized within cardiomyocytes and serve as a reservoir of active metalloproteinase in porcine female myocardium

Journal of Physiology and Pharmacology

Volumn 65, Issue 3, 2014, Pages 365-375

  Kiczak, L ^a,b   Tomaszek, A ^a,c   Bania, J ^a,b   Paslawska, U ^a,b   Zacharski, M ^a,b   Janiszewski, A ^a,b   Rybinska, I R ^a,c   Dziegiel, P ^a,c   Von Haehling, S ^d   Ardehali, H ^c,e   Jankowska, E A ^a,c   Ponikowski, P ^a,c  

^a REGIONAL SPECIALIST HOSPITAL   (Poland)

^b WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Experimental model of heart failure; Heart failure; Matrix metalloproteinase 9; Myocardial remodeling; Neutrophil gelatinase associated lipocalin; Tissue inhibitor of metalloproteinases type 1

Indexed keywords

GELATINASE B; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; LIPOCALIN;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HEART VENTRICLE PACING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC HEART FAILURE; TACHYCARDIA INDUCED CARDIOMYOPATHY; TISSUE REPAIR; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; DISEASE MODEL; ENZYMOLOGY; HEART MUSCLE; HEART VENTRICLE; METABOLISM; PATHOLOGY; SWINE;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE, SYSTOLIC; HEART VENTRICLES; HUMANS; LIPOCALINS; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; MYOCYTES, CARDIAC; SWINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84902481873     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Park SH, Hong H, Han YM, et al. Nonsteroidal anti-inflammatory drugs (NSAID) sparing effects of glucosamine hydrochloride through N-glycosylation inhibition; strategy to rescue stomach from NSAID damage. J Physiol Pharmacol 2013; 64: 157-165.
2. Lekstan A, Lampe P, Lewin-Kowalik J, et al. Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma. J Physiol Pharmacol 2012; 63: 589-599.
3. Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol 2008; 59 (Suppl. 6): 145-152.
4. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342.
5. Zamilpa R, Lindsey ML. Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol 2010; 48: 558-563.
6. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
7. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-1949.
8. Iyer RP, Patterson NL, Fields GB, Lindsey ML. The history of matrix metalloproteinases (MMPs): milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 2012; 303: H919-H930.
9. Aupperle H, Garbade J, Schubert A, et al. Effects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model. Vet Pathol 2007; 44: 494-503.
10. Aupperle H, Baldauf K, Marz I. An immunohistochemical study of feline myocardial fibrosis. J Comp Pathol 2011; 145: 158-173.
11. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999; 1: 337-352.
12. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86: 1259-1265.
13. Kolkenbrock H, Hecker-Kia A, Orgel D, Kinawi A, Ulbrich N. Progelatinase B forms from human neutrophils. complex formation of monomer/lipocalin with TIMP-1. Biol Chem 1996; 377: 529-533.
14. Woodrum DT, Ford JW, Ailawadi G, et al. Gender differences in rat aortic smooth muscle cell matrix metalloproteinase-9. J Am Coll Surg 2005; 201: 398-404.
15. Fang L, Gao XM, Moore XL, et al. Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J Mol Cell Cardiol 2007; 43: 535-544.
16. Thrailkill KM, Moreau CS, Cockrell GE, et al. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 2007; 37: 336-343.
17. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005; 96: 339-345.
18. Samnegard A, Hulthe J, Silveira A, Ericsson CG, Hamsten A, Eriksson P. Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. Atherosclerosis 2009; 202: 550-556.
19. Goldmann C, Ghofrani A, Hafemann B, et al. Combination anesthesia with ketamine and pentobarbital: a long-term porcine model. Res Exp Med (Berl) 1999; 199: 35-50.
20. Paslawska U, Gajek J, Kiczak L, et al. Development of porcine model of chronic tachycardia-induced cardiomyopathy. Int J Cardiol 2011; 153: 36-41.
21. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-189.
22. Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005; 38:73-83.
23. Masure S, Proost P, Van Damme J, Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem 1991; 198: 391-398.
24. Pfaffl MW. A new mathematical model for quantification in real-time real time PCR. Nucleic Acids Res 2001; 29: e45.
25. Mook OR, Van Overbeek C, Ackema EG, Van Maldegem F, Frederiks WM. In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J Histochem Cytochem 2003; 51: 821-829.
26. Shapiro SD, Fliszar CJ, Broekelmann TJ, Mecham RP, Senior RM, Welgus HG. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem 1995; 270: 6351-6356.
27. Yamashita C, Hayashi T, Mori T, et al. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 2007; 30: 1219-1230.
28. Leber TM, Balkwill FR. Zymography: a single-step staining method for quantitation of proteolitic activity on substrate gels. Anal Biochem 1997; 249: 24-28.
29. Barnes A, Bee A, Bell S, Gilmore W, Mee A, Morris R, Carter SD. Immunological and inflammatory characterisation of three canine cell lines: K1, K6 and DH82. Vet Immunol Immunopathol 2000; 75: 9-25.
30. Moll UM, Youngleib GL, Rosinski KB, Quigley JP. Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res 1990; 50: 6162-6170.
31. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, Squire IB. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodeling and prognosis after acute myocardial infarction. Eur Heart J 2008; 29: 2116-2124.
32. Shrestha K, Borowski AG, Troughton RW, Thomas JD, Klein AL, Tang WH. Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail 2011; 17: 472-478.
33. Yan AT, Yan RT, Spinale FG, et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006; 12: 514-519.
34. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585.
35. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006; 26: 136-142.
36. Yndestad A, Landro L, Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009; 30: 1229-1236.
37. Batlle M, Perez-Villa F, Garcia-Pras E, et al. Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients. Transplant Proc 2007; 39: 2344-2346.
38. Rastogi S, Gupta RC, Mishra S, Morita H, Tanhehco EJ, Sabbah HN. Long-term therapy with the acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure. J Heart Lung Transplant 2005; 24: 1619-1625.
39. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149.
40. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011; 278: 28-45.
41. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708-1715.
42. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996; 148: 1639-1648.
43. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001, 69: 851-859.
44. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley J P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007; 104: 20262-20267.
45. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthitis Rheum 2007; 56: 3326-3335.
46. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL) modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276: 37258-37265.
47. Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis 2010; 27: 295-305.
48. Okada Y, Gonoji Y, Naka K, et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells, purification and activation of the precursor and enzymatic properties. J Biol Chem 1992; 277: 21712-21719.
49. Tschesche H, Zoelzer V, Triebel S, Bartsch S. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 2001; 268: 1918-1928.